neuroClues raises €10 million Series A to become the brain’s stethoscope for early diagnosis of neurological disorders

French-Belgian MedTech startup neuroClues has successfully raised €10 million in Series A funding, bringing its total capital raised to €25 million. This significant investment, led by Teampact Ventures, White Fund, and the EIC Fund, underscores the growing importance of early diagnosis for neurological disorders and highlights European innovation in the health tech sector. The funding will be instrumental in scaling neuroClues' pioneering technology, which aims to transform how clinicians identify and monitor conditions like Parkinson's and Alzheimer's. The core of neuroClues' innovation lies in a compact, non-invasive, CE-marked medical device that captures and analyzes eye movements. Utilizing proprietary AI algorithms, the system extracts objective and reproducible biomarkers, offering a quantitative alternative to subjective clinical assessments. This technology allows for the detection of neurological anomalies years before visible symptoms manifest, a critical advancement given the increasing prevalence of neurodegenerative diseases and the current limitations in early detection methods. This advancement has significant implications for patient care and the broader healthcare landscape. By providing clinicians with objective data in minutes, neuroClues aims to improve diagnostic accuracy, reduce misdiagnoses, and enable earlier intervention, potentially slowing or preventing irreversible brain damage. The platform's ability to learn and become more intelligent with each deployed device positions it as a key player in developing comprehensive normative databases for oculomotor biomarkers across Europe.